January 07, 2026
Kaplan Fox & Kilsheimer LLP will continue leading a putative securities class action against Spectrum Pharmaceuticals after a previously appointed lead plaintiff was removed from the case for allegedly going behind his lawyers' backs to push his own settlement plan and unrelated conspiracy theories.
August 05, 2025
The lead plaintiff in a securities class action against Spectrum Pharmaceuticals in Manhattan federal court was removed from the case Tuesday when a federal judge found he broke confidentiality rules by going behind his lawyers' backs in an attempt to push his own settlement plan and fixating on unrelated conspiracy theories.
January 23, 2024
Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the suit adequately alleged the defendants "consciously or recklessly" made false or misleading statements.